U
ASPX

UBS’s AUSPEX PHARMACEUTICALS INC COM STK (DE) ASPX Stock Holding History

UBS’s Portfolio ASPX Stock Details ASPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,774
Closed -$40K – 11215
2014
Q2 		$40K Buy
1,774
+1,085
+157% +$23.7K ﹤0.01% 7194
2014
Q1 		$21K Buy
+689
New +$18.5K ﹤0.01% 8050

Other funds holding ASPX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS's ASPX Position: Q3 2014 in Review

UBS sold out of AUSPEX PHARMACEUTICALS INC COM STK (DE) (ASPX) in Q3 2014, closing a stake of 1,774 shares — an estimated $40K sold.

UBS first reported a position in ASPX in Q1 2014 and held it in 2 quarters. The position peaked at $40K in Q2 2014. 71 funds tracked by Wall St. Rank hold ASPX as of Q3 2014.

  • UBS reported no remaining AUSPEX PHARMACEUTICALS INC COM STK (DE) position as of Q3 2014 after selling out during the quarter.
  • UBS sold 1,774 AUSPEX PHARMACEUTICALS INC COM STK (DE) shares in Q3 2014, an estimated $40K.
  • UBS first reported a position in AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q1 2014 and held it in 2 quarters.
  • UBS's AUSPEX PHARMACEUTICALS INC COM STK (DE) position peaked at $40K in Q2 2014.
  • 71 funds tracked by Wall St. Rank held AUSPEX PHARMACEUTICALS INC COM STK (DE) as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.